Literature DB >> 22348172

Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer.

P David Mozley1, Claus Bendtsen, Binsheng Zhao, Lawrence H Schwartz, Matthias Thorn, Yuanxin Rong, Luduan Zhang, Andrea Perrone, René Korn, Andrew J Buckler.   

Abstract

OBJECTIVE: This study was designed to characterize the reproducibility of measurement for tumor volumes and their longest tumor diameters (LDs) and estimate the potential impact of using changes in tumor volumes instead of LDs as the basis for response assessments.
METHODS: We studied patients with advanced lung cancer who have been observed longitudinally with x-ray computed tomography in a multinational trial. A total of 71 time points from 10 patients with 13 morphologically complex target lesions were analyzed. A total of 6461 volume measurements and their corresponding LDs were made by seven independent teams using their own work flows and image analysis tools. Interteam agreement and overall interrater concurrence were characterized.
RESULTS: Interteam agreement between volume measurements was better than between LD measurements (ı = 0.945 vs 0.734, P = .005). The variability in determining the nadir was lower for volumes than for LDs (P = .005). Use of standard thresholds for the RECIST-based method and use of experimentally determined cutoffs for categorizing responses showed that volume measurements had a significantly greater sensitivity for detecting partial responses and disease progression. Earlier detection of progression would have led to earlier changes in patient management in most cases.
CONCLUSIONS: Our findings indicate that measurement of changes in tumor volumes is adequately reproducible. Using tumor volumes as the basis for response assessments could have a positive impact on both patient management and clinical trials. More authoritative work to qualify or discard changes in volume as the basis for response assessments should proceed.

Entities:  

Year:  2012        PMID: 22348172      PMCID: PMC3281412          DOI: 10.1593/tlo.11232

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  25 in total

Review 1.  Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence.

Authors:  P D Mozley; L H Schwartz; C Bendtsen; B Zhao; N Petrick; A J Buckler
Journal:  Ann Oncol       Date:  2010-03-23       Impact factor: 32.976

Review 2.  The FDA critical path initiative and its influence on new drug development.

Authors:  Janet Woodcock; Raymond Woosley
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

3.  The effect of measuring error on the results of therapeutic trials in advanced cancer.

Authors:  C G Moertel; J A Hanley
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

4.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

Review 5.  The use of volumetric CT as an imaging biomarker in lung cancer.

Authors:  Andrew J Buckler; James L Mulshine; Ronald Gottlieb; Binsheng Zhao; P David Mozley; Lawrence Schwartz
Journal:  Acad Radiol       Date:  2010-01       Impact factor: 3.173

Review 6.  Radiologic measurements of tumor response to treatment: practical approaches and limitations.

Authors:  Chikako Suzuki; Hans Jacobsson; Thomas Hatschek; Michael R Torkzad; Katarina Bodén; Yvonne Eriksson-Alm; Elisabeth Berg; Hirofumi Fujii; Atsushi Kubo; Lennart Blomqvist
Journal:  Radiographics       Date:  2008 Mar-Apr       Impact factor: 5.333

7.  Use of body scanner in radiotherapy treatment planning.

Authors:  J E Munzenrider; M Pilepich; J B Rene-Ferrero; I Tchakarova; B L Carter
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

8.  Computerized tomography in the quantitative assessment of tumour response.

Authors:  J M Quivey; J R Castro; G T Chen; A Moss; W M Marks
Journal:  Br J Cancer Suppl       Date:  1980-04

9.  Effect of nodule characteristics on variability of semiautomated volume measurements in pulmonary nodules detected in a lung cancer screening program.

Authors:  Ying Wang; Rob J van Klaveren; Hester J van der Zaag-Loonen; Geertruida H de Bock; Hester A Gietema; Dong Ming Xu; Anne L M Leusveld; Harry J de Koning; Ernst T Scholten; Johny Verschakelen; Mathias Prokop; Matthijs Oudkerk
Journal:  Radiology       Date:  2008-08       Impact factor: 11.105

10.  X-ray computed tomography: semiautomated volumetric analysis of late-stage lung tumors as a basis for response assessments.

Authors:  C Bendtsen; M Kietzmann; R Korn; P D Mozley; G Schmidt; G Binnig
Journal:  Int J Biomed Imaging       Date:  2011-05-24
View more
  37 in total

1.  Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.

Authors:  M Nishino; D M Jackman; P J DiPiro; H Hatabu; P A Jänne; B E Johnson
Journal:  Clin Radiol       Date:  2014-05-22       Impact factor: 2.350

2.  A mathematical simulation to assess variability in lung nodule size measurement associated with nodule-slice position.

Authors:  Krishna Juluru; Noor Al Khori; Sha He; Amy Kuceyeski; John Eng
Journal:  J Digit Imaging       Date:  2015-06       Impact factor: 4.056

3.  Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.

Authors:  Mizuki Nishino; Adrian G Sacher; Leena Gandhi; Zhao Chen; Esra Akbay; Andriy Fedorov; Carl F Westin; Hiroto Hatabu; Bruce E Johnson; Peter Hammerman; Kwok-Kin Wong
Journal:  Eur J Radiol       Date:  2016-12-26       Impact factor: 3.528

4.  Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients.

Authors:  Sree Harsha Tirumani; Atul B Shinagare; Ailbhe C O'Neill; Mizuki Nishino; Michael H Rosenthal; Nikhil H Ramaiya
Journal:  Eur Radiol       Date:  2015-05-20       Impact factor: 5.315

5.  Quantitative analysis of tumor volume reduction after three-dimensional conformal radiation therapy for intracranial meningiomas.

Authors:  Nam Kwon Lee; Chul Yong Kim; Won Sup Yoon; Yong Gu Chung; Nam Joon Lee
Journal:  J Neurooncol       Date:  2014-10-08       Impact factor: 4.130

6.  Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.

Authors:  Maryam Aghighi; Justin Boe; Jarrett Rosenberg; Rie Von Eyben; Rakhee S Gawande; Philippe Petit; Tarsheen K Sethi; Jeremy Sharib; Neyssa M Marina; Steven G DuBois; Heike E Daldrup-Link
Journal:  Radiology       Date:  2016-03-16       Impact factor: 11.105

7.  Immune Modulation Therapy and Imaging: Workshop Report.

Authors:  Anthony F Shields; Paula M Jacobs; Mario Sznol; Michael M Graham; Ron N Germain; Lawrence G Lum; Elizabeth M Jaffee; Elisabeth G E de Vries; Sridhar Nimmagadda; Annick D Van den Abbeele; David K Leung; Anna M Wu; Elad Sharon; Lalitha K Shankar
Journal:  J Nucl Med       Date:  2017-08-17       Impact factor: 10.057

8.  Assessment of Glioma Response to Radiotherapy Using Multiple MRI Biomarkers with Manual and Semiautomated Segmentation Algorithms.

Authors:  Yang Yu; Dong-Hoon Lee; Shin-Lei Peng; Kai Zhang; Yi Zhang; Shanshan Jiang; Xuna Zhao; Hye-Young Heo; Xiangyang Wang; Min Chen; Hanzhang Lu; Haiyun Li; Jinyuan Zhou
Journal:  J Neuroimaging       Date:  2016-04-29       Impact factor: 2.486

9.  Desmoid fibromatosis: MRI features of response to systemic therapy.

Authors:  Pooja J Sheth; Spencer Del Moral; Breelyn A Wilky; Jonathan C Trent; Jonathan Cohen; Andrew E Rosenberg; H Thomas Temple; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2016-08-09       Impact factor: 2.199

10.  Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.

Authors:  Mizuki Nishino; Suzanne E Dahlberg; Linnea E Fulton; Subba R Digumarthy; Hiroto Hatabu; Bruce E Johnson; Lecia V Sequist
Journal:  Acad Radiol       Date:  2016-01-08       Impact factor: 3.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.